re.Mind Capital

Motif Neurotech develops minimally invasive bioelectronic implants aimed at monitoring and treating severe mental illnesses, particularly treatment-resistant depression. The company focuses on wireless power and data technologies, which facilitate the creation of new, miniature implants designed for tissue stimulation and diagnostic readings. These innovative implants enable patients to repair neural circuits through electronic therapies, offering a promising approach to address complex mental health challenges.

Precision Neuroscience is a company focused on developing advanced brain-computer interface technology aimed at offering innovative treatments for the approximately one billion individuals worldwide affected by neurological disorders. Founded in 2021 and based in New York, the company's technology is characterized by its minimally invasive design, safety for removal, and capacity for processing substantial data. This platform enables medical professionals to establish a direct connection between the human brain and artificial intelligence, potentially transforming the landscape of neurological care.

Sensorium Therapeutics is a drug discovery platform based in Boston, Massachusetts, that focuses on developing novel FDA-approved psychoactive medicines. Founded in 2021, the company utilizes an artificial intelligence product engine to discover and develop drugs targeting central nervous system diseases. By integrating historical human efficacy data from natural compounds, Sensorium Therapeutics aims to create new medicines characterized by innovative pharmacology and improved clinical success rates. This approach enables pharmaceutical companies to enhance their drug development processes effectively.

iLoF, or Intelligent Lab on Fiber, is a developer of a digital health platform that utilizes advanced photonics and artificial intelligence to enhance personalized drug discovery and development. The company has created a patented system that identifies and captures unique features of gold-standard biomarkers, compiling this information into a cloud-based library. By leveraging this extensive database, iLoF aims to facilitate collaboration among physicists, biologists, and data scientists, ultimately improving the efficiency and patient-centricity of clinical trials. This innovative approach not only reduces the costs associated with drug development but also aims to provide patients with tailored, life-saving treatments.

Alena is a healthcare technology company founded in 2019 in London that focuses on addressing mental health disorders through innovative methods. The company develops a medical device application that employs neuroscience-based games to assess user behavior and identify thinking patterns associated with key mental health issues, particularly social anxiety. By leveraging insights from computational neuroscience and psychiatry, Alena's application suggests optimal interventions tailored to individual needs and dynamically adapts to users' changing circumstances. This approach combines evidence-based therapy with neuroscience, enabling users to manage stress and overcome anxiety more effectively.

Rejuveron Life Sciences AG is a biotechnology company based in Zug, Switzerland, founded in 2019. The company focuses on developing and investing in innovative drugs and technologies aimed at promoting healthy aging and extending lifespan. As a fully integrated platform, Rejuveron combines its investment strategies with a commitment to advancing therapies that address age-related conditions, leveraging both scientific research and entrepreneurial initiatives in the life sciences sector.

OccamzRazor specializes in enhancing drug discovery and development through the integration of machine learning and advanced biological techniques. The company's innovative analysis pipeline employs two proprietary technologies, Panoramic AI and RazorBrain, which work together to extract valuable data from both unstructured sources, such as biomedical publications and patient-reported outcomes, and structured datasets, including genomics and proteomics. This comprehensive approach allows for the generation of robust drug discovery hypotheses and insights. OccamzRazor has successfully applied its platform to various applications, including biomedical text data extraction, novel target identification, and drug repurposing. Furthermore, the company is focused on developing a neuroscience therapeutics platform aimed at addressing Parkinson's Disease by creating an exhaustive knowledge graph that synthesizes existing biomedical data, ultimately supporting healthcare professionals in therapeutic strategy and drug development.

CereGate GmbH is a brain-machine interface company based in Hamburg, Germany, with an additional office in San Diego, California. Founded in 2019, the company specializes in developing a computer-brain interface (CBI) technology designed to enhance medical treatments by facilitating the direct transmission of information to neural circuits through existing neuromodulation implants. This innovative platform aims to improve the programming of neuromodulation systems, offering novel therapeutic options for patients with neurological disorders or sensory deficits. By enabling new forms of communication and sensory substitution, CereGate's technology provides patients with opportunities to adapt and improve their conditions, fostering greater independence and quality of life.

OpenBCI is an innovative company focused on developing an open-source brain-computer interface designed to make neurotechnology more accessible. By offering low-cost, programmable EEG platforms, OpenBCI enables users to interface with brain activity and other biosignals, such as muscle and heart activity. Their tools are aimed at reducing barriers to entry in the fields of biosensing and neuroscience, allowing researchers and hobbyists alike to obtain research-grade EEG recordings. The company fosters a collaborative community of scientists, engineers, and makers who contribute to the ongoing development of hardware and software solutions. Unlike traditional BCI companies that provide fixed devices with limited access to their algorithms, OpenBCI’s open-source approach encourages experimentation and customization, making it a valuable resource for those engaged in research and development in brain-computer interfacing. This platform serves as a flexible foundation for exploration in the rapidly evolving field of neurotechnology.

Kanna Health is a preclinical stage biotechnology company focused on developing innovative therapeutics derived from kanna, or Sceletium tortuosum, a medicinal succulent used for centuries by the San hunter-gatherers of South Africa. The company aims to address significant unmet needs in sexual and mental health through its lead candidate, KH-001, which is based on alkaloids found in kanna. This candidate is designed to enhance mood and performance in men, offering potential treatments that are both effective and affordable.

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel neuroplasticity-promoting therapeutics—to better treat mental health disorders at scale. The company was founded in 2019 and is headquartered in Boston, Massachusetts.

Tripp Inc. is a company focused on developing a digital psychedelic wellness platform that utilizes virtual and augmented reality to enhance emotional well-being. Founded in 2016 and headquartered in Los Angeles, California, with a satellite office in Chicago, the company creates immersive experiences that combine audio, visual elements, and gameplay mechanics to promote mindfulness and transformation. Tripp’s offerings are informed by scientific research indicating that interactive digital experiences can positively influence brain function. Through its platform, the company delivers wellness solutions designed to help users manage their emotions, reduce stress and anxiety, and achieve a state of calm and focus.

Ksana Health is a company based in Eugene, Oregon, founded in 2019, that specializes in digital mental health solutions. The company has developed a platform aimed at collecting and transferring mental health data from users to healthcare practitioners via an app. This platform provides personalized behavioral insights and just-in-time interventions, enabling continuous remote monitoring of patients. Additionally, it offers digital therapeutics designed to enhance mental health outcomes. Through its innovative approach, Ksana Health seeks to improve the accessibility and effectiveness of mental health care.

Synchron is a medical technology company focused on developing innovative brain-computer interface solutions. It manufactures an implantable device known as the stentrode, which is delivered to the brain via a catheter. This minimally invasive device is embedded with electrode arrays that can interpret neuronal signals and modulate neural activity in targeted areas. By enabling patients with motor impairments to control digital devices, prosthetics, and other assistive technologies through thought, Synchron aims to enhance the quality of life for individuals with disabilities.

Blackrock Neurotech is a company dedicated to developing advanced neurotechnology platforms designed to record bio-potentials from both the central and peripheral nervous systems for chronic and acute applications. The company's precision electrode technology is pivotal in numerous global innovations related to brain-computer interfaces (BCI) and neural signal processing and stimulation. Blackrock Neurotech aims to assist individuals with disabilities, enabling them to walk, talk, see, hear, and feel by providing the clinical community with innovative tools and expertise to create novel implantable solutions that enhance human lives.

CB Therapeutics is a biotechnology company focused on the biosynthetic production of cannabinoids and tryptamines from sugar, utilizing a cellular agriculture platform. By employing yeast instead of traditional plant sources, the company produces pure cannabinoids, including CBD and THC, as well as psychedelic compounds and their analogs. This innovative approach aims to support clinical research for a range of serious health conditions, particularly in mental health, while promoting advancements in treatment options. CB Therapeutics seeks to enhance the healthcare industry’s capacity to address various diseases and improve overall healthspan.